Cancer Treatment Indications Quiz
14 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the recommended treatment for unresectable or metastatic melanoma?

  • No treatment recommended
  • Combination chemotherapy
  • Single-agent therapy
  • Adjuvant treatment (correct)

    • Which therapy is indicated for patients with relapsed or refractory classical Hodgkin lymphoma?

  • Adjuvant treatment
  • Single-agent therapy (correct)
  • Combination therapy
  • No treatment required

    • How long should treatment for microsatellite instability-high cancer continue?

  • Until disease progression or unacceptable toxicity (correct)
  • Indefinitely
  • Up to 24 months without disease progression (correct)
  • For a maximum of 12 months

    • What is the primary combination therapy for HER2-positive gastric cancer?

    <p>Combination with trastuzumab and chemotherapy</p> Signup and view all the answers

    Which cancer is indicated for combination therapy with axitinib?

    <p>Renal cell carcinoma</p> Signup and view all the answers

    What treatment is indicated for locally advanced, unresectable HER2-negative gastric cancer?

    <p>Combination with fluoropyrimidine and platinum</p> Signup and view all the answers

    What is a key treatment option for patients with cutaneous squamous cell carcinoma?

    <p>Combination of therapies including immunotherapy</p> Signup and view all the answers

    What defines the criteria for microsatellite instability-high colorectal cancer treatment?

    <p>No satisfactory alternative treatment options available</p> Signup and view all the answers

    In treating malignant pleural mesothelioma, what is the primary combination used?

    <p>Combination with pemetrexed and platinum chemotherapy</p> Signup and view all the answers

    What therapy is indicated for blue for unresectable or metastatic tumor mutational burden-high solid tumors?

    <p>Indicated for patients with no satisfactory alternative treatment options</p> Signup and view all the answers

    When treating head and neck squamous cell carcinoma, which therapy is an option?

    <p>Combination chemotherapy or single-agent therapy</p> Signup and view all the answers

    What defines the duration of therapy for classical Hodgkin lymphoma?

    <p>Up to 24 months without disease progression</p> Signup and view all the answers

    What is the main therapeutic approach for treating hepatocellular carcinoma linked to hepatitis B?

    <p>Indicated after prior systemic therapy other than a PD1/PD-L1-containing regimen</p> Signup and view all the answers

    What is the standard treatment duration for combination therapy in renal cell carcinoma?

    <p>Until disease progression or unacceptable side effects</p> Signup and view all the answers

    Study Notes

    Cancer Treatment Indications

    • Melanoma (unresecable/metastatic): Adjuvant treatment options exist.
    • Non-Small Cell Lung Cancer (NSCLC): Single-agent therapy for localized and advanced disease. Combination therapy for resectable and metastatic disease.
    • Head & Neck Squamous Cell Carcinoma: Single-agent and combination therapies available.
    • Classical Hodgkin Lymphoma (cHL): Indicated for relapsed or refractory cHL. Dose: 200 mg IV q3Weeks or 400 mg q6Weeks until disease progression, unacceptable toxicity, or 24 months without progression.

    Lymphoma Treatment

    • Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Indicated for refractory or relapsed (after ≥2 prior lines of therapy) PMBCL. Same dosage as cHL (200 mg IV q3Weeks, or 400 mg q6Weeks).
    • Different dosages for various cancer types: Dosages and schedules vary based on the specific cancer type.

    Other Cancer Indications

    • Urothelial Carcinoma: Single-agent or combination therapy (with enfortumab) is an option.
    • Microsatellite Instability-High (MSI-H)/Mismatch Repair Deficient (dMMR) Cancers: 200 mg IV q3Weeks or 400 mg q6Weeks until progression, unacceptable toxicity, or 24 months without progression. Targets solid tumors that have progressed after prior treatment.
    • Colorectal Cancer (MSI-H/dMMR): 200 mg IV q3Weeks or 400 mg IV q6Weeks until disease progression, unacceptable toxicity, or 24 months.
    • Gastric Cancer (HER2-positive): Combination therapy with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy indicated for first-line treatment.
    • Gastric Cancer (HER2-negative): Same combination therapy as above, but for HER2-negative gastric/GEJ adenocarcinoma.
    • Esophageal Cancer: Indicated for treating recurrent locally advanced or metastatic esophageal/GEJ carcinoma in patients ineligible for surgery or radiation.
    • Cervical Cancer: Available as single-agent, combination chemotherapy, or combination chemoradiotherapy.
    • Hepatocellular Carcinoma (HCC): Indicated for patients with hepatitis B-related HCC who have received prior systemic therapy (except regimens containing PD-1/PD-L1 inhibitors); Same dosage as above.
    • Merkel Cell Carcinoma (MCC): Indicated for recurrent, locally advanced, or metastatic MCC. Dosage same as above.
    • Renal Cell Carcinoma (RCC): Available in combination with axitinib or lenvatinib as combination therapy, and may have adjuvant treatment options.
    • Endometrial Cancer: Combination therapy with lenvatinib and carboplatin/paclitaxel are options. Can also be a single agent treatment.
    • Tumor Mutational Burden-High (TMB-H) Cancers (≥10 mutations/megabase [mut/Mb]): 200 mg IV q3Weeks or 400 mg q6Weeks until progression, unacceptable toxicity, or 24 months without progression. Targets solid tumors that have progressed following prior treatment.
    • Cutaneous Squamous Cell Carcinoma (cSCC): For recurrent/metastatic cSCC or locally advanced cSCC incurable by surgery or radiation; same dosage scheme.
    • Breast Cancer (High-risk early-stage TNBC and Locally recurrent unresectable or metastatic TNBC): Treatment options exist for both.
    • Biliary Tract Cancer (BTC): Combination therapy with gemcitabine and cisplatin is an option. Administered before chemotherapy when given on the same day.

    Important Notes

    • Specific dosages, schedules, and durations of treatment should be confirmed with a healthcare professional for optimal management.
    • These notes do not constitute medical advice.
    • Conditions and treatment vary greatly among patients.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    Test your knowledge on various cancer treatment indications including melanoma, lung cancer, and lymphoma. This quiz covers both single-agent and combination therapies, as well as specific dosage recommendations for different cancer types. Perfect for students and professionals in oncology!

    More Like This

    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser